|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This work shows that ERK inhibitors are effective in LKB1 and LKB1/KRAS mutated tumors, thus offering a therapeutic strategy for this prognostically unfavorable subgroup of patients.
|
31634668 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Intriguingly, however, analogous oncogenic mutations in the downstream effector kinase ERK have not been described or validated <i>in vivo</i> To determine if a point mutation could render ERK intrinsically active and oncogenic, we have assayed in <i>Drosophila</i> the effects of a mutation that confers constitutive activity upon a yeast ERK ortholog, and which has been also identified in a few human tumors.
|
31740452 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the combination of an MEK or ERK inhibitor with a first-generation (eg, erlotinib) or second-generation (eg, afatinib) EGFR-TKI also very effectively inhibited the growth of osimertinib-resistant cells in vitro and of tumors in vivo, although these cell lines were cross-resistant to first-generation or second-generation EGFR-TKIs.
|
31821539 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, VPS33B as a tumor suppressor is easily dysregulated by chemical carcinogens and it interacts with NESG1 to modulate the EGFR/RAS/ERK/c-Myc/p53/miR-133a-3p feedback loop and thus suppress the malignant phenotype of CRC.
|
31125123 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the circumstance of miR-145 elevation or HOXA1 depletion, the SCC-9 cell line manifested with inhibited cell viability, invasion, and migration <i>in vitro</i>, coupled with reduced tumor growth <i>in vivo</i>, with a decreased expression of ERK/MAPK signaling pathway-related genes/proteins.
|
31138758 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reduction in tumor diameter negatively correlated with p-ERK change in tumor (Spearman ρ = -0.71; <i>P</i> = 0.05).
|
31186313 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Conclusion:</b> SEMA3C is correlated with poor prognosis of cervical cancer patients and promotes tumor growth via the activation of the p-ERK pathway.
|
31649890 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, NK cells showed increased levels of phospho-ERK and phospho-STAT5 when co-cultured with cetuximab-coated tumors and ALT-803.
|
31338557 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PAC010 model showed increased cell proliferation (Ki-67 staining) and markers indicating survival (increased p-AKT, p-ERK and p-NF-kB65 and suppression of cleaved PARP).
|
30899378 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
GPR1 knockdown suppressed proliferation, invasion, and Akt and ERK phosphorylation in vitro and slowed tumor growth in vivo.
|
31241986 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNA-seq analysis revealed that ARQ531 constrained tumor cell proliferation and survival through Bruton's tyrosine kinase and transcriptional program dysregulation, with proteasome-mediated MYB degradation and depletion of short-lived proteins that are crucial for tumor growth and survival, including ERK, MYC and MCL1.
|
31624110 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silymarin was revealed to reduce tumor growth through inhibition of p‑ERK and activation of p‑p38 and p‑JNK in human gastric cancer cells.
|
31485597 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the case of BRAF-V600E mutant melanoma, ERK inhibition has emerged as a viable clinical approach to abrogate signaling through the ERK pathway, even in cases where MEK and Raf inhibitor treatments fail to induce tumor regression due to resistance mechanisms.
|
31190430 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Meanwhile, treating GC cells with human recombinant FGF18 or FGF18-conditioned medium accelerated tumor growth through activation of ERK-MAPK signaling.
|
30082912 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF1A encodes a tumor suppressor that inhibits the RAS→RAF→MEK→ERK pathway and is one of the most frequently inactivated genes in human cancers.
|
31435022 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inhibition of BRAF<sup>V600E</sup> in transgenic and orthotopic mouse models significantly reduced the tumor burden as well as LOX and p-ERK expression.
|
30398411 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
|
31308216 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, patients with RAS/RAF/MEK/ERK pathway mutations (38.5%) showed significantly better tumour response (p = 0.028), PFS (5.4 vs. 3.5 months, p = 0.010) and OS (10.8 vs. 5.9 months, p = 0.160) than wild type.
|
31312030 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ribosomal S6 Kinase 2 (RSK2) is a downstream target of ERK1/2 in MAPK/ERK pathway and inhibition of RSK2 suppresses the tumorigenesis and metastasis of neoplasm.
|
31207212 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The regulation of the PI3K/AKT and ERK/MAPK signaling pathways might be the underlying mechanism of the tumor suppressor role of lncRNA-PICART1.
|
30720166 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hinokitiol rapidly induced ERK phosphorylation followed by a sustained dephosphorylation, which accompanied with an increase in expression of tumor suppressor MKP-3 (mitogen-activated protein kinase phosphatase-3).
|
30684529 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These years, RAF/MEK/ERK-mediated cell signaling pathway has been discovered to inhibit the growth of tumors.
|
31760084 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 4-year progression-free survival rate, but not overall survival rate, was significantly higher in patients with KRAS-negative tumors than in those with KRAS-positive tumors (<i>P</i> < 0.05), whereas BRAF, MEK, and ERK expression was unrelated to survival.
|
30809081 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings identify the FAK-ERK activation in cell/matrix adhesion in the malignant progression of ovarian cancer and the efficiency of BAPN or MEKi for tumor suppression, providing an impetus for further studies to explore the possibility of new anticancer therapeutic combinations.
|
29458390 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
|
29129563 |
2018 |